Phase 1 Refractory B-Cell Lymphoma Clinical Trials
6 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Relapsed and/or Refractory B-cell Lymphoma
Kite, A Gilead Company247 enrolled18 locationsNCT04989803
Recruiting
Phase 1Phase 2
Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology
B-cell Lymphoma RecurrentRefractory B-Cell Lymphoma
Instituto de Investigación Biomédica de Salamanca27 enrolled8 locationsNCT06378190
Recruiting
Phase 1Phase 2
Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
Relapsed/Refractory B-cell Lymphoma
Shenzhen University General Hospital20 enrolled1 locationNCT07508605
Recruiting
Phase 1Phase 2
Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
Relapsed/Refractory B-cell Lymphoma
Shenzhen University General Hospital20 enrolled1 locationNCT07097207
Recruiting
Phase 1
L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma
Relapsed/Refractory B-cell Lymphomas
Henan Cancer Hospital22 enrolled1 locationNCT06478381
Recruiting
Phase 1
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited60 enrolled2 locationsNCT06445517